首页> 外文期刊>Pharmacology & Pharmacy >Risk Factors for Cancer Chemotherapy-Induced Hiccups (CIH)
【24h】

Risk Factors for Cancer Chemotherapy-Induced Hiccups (CIH)

机译:癌症化疗引起的打H(CIH)的危险因素

获取原文
       

摘要

Background : Hiccups are common somatic side effects of medication. Our previous analysis of the clinical risk factors for hiccups identified chemotherapy as a factor related to hiccup risk. Therefore, in the present study, we investigated the risk factors for hiccups associated with chemotherapy. Methods: We included all patients who received cancer chemotherapy and were hospitalized at the Musashino Red Cross Hospital between April 2014 and December 2014. We investigated patient demographics, physical characteristics, and other clinical factors to identify the risk factors for chemotherapy-induced hiccups (CIH). We conducted univariate and multivariable analysis to compare the CIH group and the non-CIH and determined risk factors of CIH. Results: Hiccups were identified in 48 of 292 patients with an incidence rate of 16.4%. Univariate analysis revealed that the male gender, pain, and nausea and vomiting were related to CIH. It also showed that cisplatin, pemetrexed, gemcitabine, etoposide, dexamethasone, and metoclopramide were related to CIH.A correlation which was found with doses of cisplatin, pemetrexed, gemcitabine, and etoposide. Multivariable analysis identified male gender (OR, 72.69; 95% CI, 6.95 - 757.64), nausea and vomiting (OR, 52.01; 95% CI, 3.93 - 447.13), dexamethasone (OR, 4.55; 95% CI, 1.12 - 16.91), cisplatin (OR, 3.84; 95% CI, 1.52 - 9.70), and etoposide (OR, 3.72; 95% CI, 1.14 - 12.11) as independent risk factors for hiccups. Conclusions: T he present study is the first one to report risk factors for the development of CIH. Our results suggest that male gender, having nausea, and the drugs dexamethasone, cisplatin, and etoposide are important risk factors for CIH. These results may assist in elucidation of the underlying mechanisms and guide therapy to reduce hiccup risk.
机译:背景:打ic是药物治疗的常见躯体副作用。我们先前对打h的临床危险因素的分析将化疗确定为与打risk危险相关的因素。因此,在本研究中,我们调查了与化学疗法相关的打h危险因素。方法:我们纳入了2014年4月至2014年12月期间在武藏野红十字会医院住院的所有接受过化学疗法化疗的患者。我们调查了患者的人口统计资料,身体特征和其他临床因素,以确定发生化疗诱发打ic的危险因素)。我们进行了单变量和多变量分析,以比较CIH组和非CIH组以及确定的CIH危险因素。结果:292例患者中有48例出现打H,发生率16.4%。单因素分析表明,男性,疼痛,恶心和呕吐与CIH有关。研究还表明,顺铂,培美曲塞,吉西他滨,依托泊苷,地塞米松和甲氧氯普胺与CIH有关。与顺铂,培美曲塞,吉西他滨和依托泊苷的剂量存在相关性。多变量分析确定了男性性别(OR,72.69; 95%CI,6.95-757.64),恶心和呕吐(OR,52.01; 95%CI,3.93-447.13),地塞米松(OR,4.55; 95%CI,1.12-16.91) ,顺铂(OR,3.84; 95%CI,1.52-9.70)和依托泊苷(OR,3.72; 95%CI,1.14-12.11)作为打h的独立危险因素。结论:本研究是第一个报告CIH发展危险因素的研究。我们的研究结果表明,患有恶心的男性,地塞米松,顺铂和依托泊苷等药物是CIH的重要危险因素。这些结果可能有助于阐明潜在的机制并指导治疗以减少打ic风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号